Virginia Center for Reproductive Medicine, 11150 Sunset Hills Rd, Suite 100, Reston, VA, 20190, USA.
Department of Obstetrics and Gynecology, George Washington University, Washington, DC, USA.
J Assist Reprod Genet. 2021 May;38(5):1003-1012. doi: 10.1007/s10815-021-02146-9. Epub 2021 Mar 15.
Platelet-rich plasma (PRP) has become a novel treatment in various aspects of medicine including orthopedics, cardiothoracic surgery, plastic surgery, dermatology, dentistry, and diabetic wound healing. PRP is now starting to become an area of interest in reproductive medicine more specifically focusing on infertility. Poor ovarian reserve, menopause, premature ovarian failure, and thin endometrium have been the main areas of research. The aim of this article is to review the existing literature on the effects of autologous PRP in reproductive medicine providing a summation of the current studies and assessing the need for additional research.
A literature search is performed using PubMed, MEDLINE, and CINAHL Plus to identify studies focusing on the use of PRP therapy in reproductive medicine. Articles were divided into 3 categories: PRP in thin lining, PRP in poor ovarian reserve, and PRP in recurrent implantation failure.
In women with thin endometrium, the literature shows an increase in endometrial thickness and increase in chemical and clinical pregnancy rates following autologous PRP therapy. In women with poor ovarian reserve, autologous intraovarian PRP therapy increased anti-Mullerian hormone (AMH) levels and decreased follicle-stimulating hormone (FSH), with a trend toward increasing clinical and live birth rates. This trend was also noted in women with recurrent implantation failure.
Limited literature shows promise in increasing endometrial thickness, increasing AMH, and decreasing FSH levels, as well as increasing chemical and clinical pregnancy rates. The lack of standardization of PRP preparation along with the lack of large randomized controlled trials needs to be addressed in future studies. Until definitive large RCTs are available, PRP use should be considered experimental.
富含血小板的血浆(PRP)已成为医学各领域的一种新型治疗方法,包括骨科、心胸外科、整形外科学、皮肤科、牙科和糖尿病创面愈合。PRP 现在开始成为生殖医学领域的一个研究热点,特别是在不孕不育方面。卵巢储备功能不良、绝经、卵巢早衰和薄型子宫内膜一直是主要的研究领域。本文旨在综述 PRP 在生殖医学中的应用的现有文献,总结当前研究,并评估进一步研究的必要性。
通过 PubMed、MEDLINE 和 CINAHL Plus 进行文献检索,以确定关注 PRP 治疗在生殖医学中的应用的研究。文章分为 3 类:PRP 在薄型子宫内膜中的应用、PRP 在卵巢储备功能不良中的应用和 PRP 在反复着床失败中的应用。
在薄型子宫内膜的女性中,文献表明,自体 PRP 治疗可增加子宫内膜厚度,并提高化学妊娠率和临床妊娠率。在卵巢储备功能不良的女性中,自体卵巢内 PRP 治疗可增加抗苗勒管激素(AMH)水平,降低卵泡刺激素(FSH)水平,临床妊娠率和活产率呈上升趋势。这一趋势在反复着床失败的女性中也有出现。
有限的文献表明,增加子宫内膜厚度、增加 AMH 和降低 FSH 水平以及提高化学妊娠率和临床妊娠率具有一定的前景。PRP 制备缺乏标准化以及缺乏大型随机对照试验的问题需要在未来的研究中解决。在有明确的大型 RCT 结果之前,PRP 的应用应被视为实验性的。